COVID-19 pneumonia causes diffuse alveolar damage. This passes through three stages, an initial exudative phase where there is minimal exudation of fluid into the alveoli. As a result, imaging appearances will be negative or subtle abnormalities off ground glass will be seen. Subsequently, with increased

COVID-19 pneumonia causes diffuse alveolar damage. This passes through three stages, an initial exudative phase where there is minimal exudation of fluid into the alveoli. As a result, imaging appearances will be negative or subtle abnormalities off ground glass will be seen. Subsequently, with increased

COVID-19 pneumonia causes diffuse alveolar damage. This passes through three stages, an initial exudative phase where there is minimal exudation of fluid into the alveoli. As a result, imaging appearances will be negative or subtle abnormalities off ground glass will be seen. Subsequently, with increased

COVID-19 pneumonia causes diffuse alveolar damage. This passes through three stages, an initial exudative phase where there is minimal exudation of fluid into the alveoli. As a result, imaging appearances will be negative or subtle abnormalities off ground glass will be seen. Subsequently, with increased

COVID-19 pneumonia causes diffuse alveolar damage. This passes through three stages, an initial exudative phase where there is minimal exudation of fluid into the alveoli. As a result, imaging appearances will be negative or subtle abnormalities off ground glass will be seen. Subsequently, with increased

COVID-19 pneumonia causes diffuse alveolar damage. This passes through three stages, an initial exudative phase where there is minimal exudation of fluid into the alveoli. As a result, imaging appearances will be negative or subtle abnormalities off ground glass will be seen. Subsequently, with increased

COVID-19 pneumonia causes diffuse alveolar damage. This passes through three stages, an initial exudative phase where there is minimal exudation of fluid into the alveoli. As a result, imaging appearances will be negative or subtle abnormalities off ground glass will be seen. Subsequently, with increased

COVID-19 pneumonia causes diffuse alveolar damage. This passes through three stages, an initial exudative phase where there is minimal exudation of fluid into the alveoli. As a result, imaging appearances will be negative or subtle abnormalities off ground glass will be seen. Subsequently, with increased

COVID-19 pneumonia causes diffuse alveolar damage. This passes through three stages, an initial exudative phase where there is minimal exudation of fluid into the alveoli. As a result, imaging appearances will be negative or subtle abnormalities off ground glass will be seen. Subsequently, with increased

COVID-19 pneumonia causes diffuse alveolar damage. This passes through three stages, an initial exudative phase where there is minimal exudation of fluid into the alveoli. As a result, imaging appearances will be negative or subtle abnormalities off ground glass will be seen. Subsequently, with increased
Figure 4 (A-C): HRCT (A) reveals typical subpleural ground-glass densities. HRCT (B) after 7 days of first scan reveals transition of ground-glass densities to dense consolidation with reticular opacities. HRCT (C) 45 days after first scan reveals nearly total resolution with minimal ground-glass densities.

Figure 5 (A-C): HRCT (A) reveals typical peripheral subpleural ground-glass densities as well as peribronchovascular densities. HRCT (B) after 5 days reveals evolution of ground-glass densities to consolidation and reticular abnormalities. HRCT (C) 200 days after first scan reveals clearing of all abnormalities.

Figure 6 (A-D): HRCT (A) typical peripheral ground-glass and consolidations in subpleural regions. HRCT (B) 9 days after first scan evolve into consolidations, reticular abnormalities resembling organising pneumonia. HRCT (C) 25 days after first scan consolidations resolved with minimal ground-glass densities and subpleural curvilinear lines. HRCT (D) CT study at day 98 from first scan reveals total clearing of all abnormalities also subpleural curvilinear lines which is often reported as fibrosis.

Figure 7 (A-D): Series of HRCT images in coronal plane demonstrating the evolution of COVID-19 pneumonia. HRCT (A) normal, HRCT (B) ground-glass densities, HRCT (C) consolidations with septal thickenings, HRCT (D) residual reticular opacities of organising pneumonia which with time should resolve.
Figure 8 (A-D): HRCT (A) early in disease reveals no abnormality. HRCT (B) 7 days after first scan reveals peribronchovascular ill-defined consolidations. HRCT (C) 27 days after first scan demonstrate resolution of the consolidations. HRCT (D) 62 days after first scan shows near total resolution.

Figure 9 (A-C): HRCT (A) demonstrates subtle ground-glass densities in right posterior subpleural region of lower lobe. HRCT (B) 8 days later, COVID-19 pneumonia evolves with subpleural and peribronchovascular ground-glass densities and consolidations. HRCT (C) 40 days after first scan reveals total resolution of abnormalities.

Figure 10 (A and B): HRCT (A) demonstrates subpleural and peribronchovascular ground-glass, consolidations and reticular abnormalities which totally resolved in HRCT (B) done after 60 days.

Figure 11: HRCT (A) COVID-19 pneumonia in resolving phase with subpleural curvilinear lines often termed fibrosis this on follow up scan shows total resolution.

Figure 12 (A-D): HRCT (A) demonstrates typical COVID-19 pneumonia in inflammatory stage with ground-glass densities/consolidations in subpleural location. HRCT (B) after 11 days progressed to fibro proliferative phase with ground-glass densities transiting to organising pneumonia HRCT (C) after 45 days organising pneumonia clears with residual ground-glass densities. HRCT (D) after 112 days shows resolution of all abnormalities.
Figure 13 (A-C): HRCT (A) shows typical COVID19 pneumonia with subpleural distribution of ground glass densities. HRCT (B) after 30 days shows ground glass densities turning into extensive consolidation and reticular abnormalities HRCT (C) after 155 days shows considerable resolution.

Figure 14 (A-D): HRCT (A) Reveals subpleural ground glass densities typical of COVID 19 pneumonia Follow up study after 40 days (B) reveals subpleural and peribronchovascular interstitial thickening which shows mild regression on follow up scans done 110 (C) and 170 days (D) post first scan. Persistence of these findings after 6 months raises the possibility of true fibrosis though further follow up will be useful as there appears to be a mild persistent regression.

Figure 15: HRCT (A) revels subpleural ground glass of covid pneumonia Follow up after 10 days reveals ground glass has evolved to consolidation in subpleural regions which further resolves to subpleural curvilinear line on HRCT (C) done after 62 days of first scan. Final scan (D) after 135 days reveals persistence of subpleural curvilinear line.
Kohli: Residual changes on CT scan are they all fibrosis?

Exudation into the alveoli it passes into the next stage, an inflammatory stage. Depending on the extent of alveolar exudation the appearances on imaging are ground glass densities, consolidation or a combination of these. Finally, the diffuse alveolar damage passes into a reparative phase where there is proliferation of epithelial cells and fibroblasts with collagen deposition. On imaging the appearances in this stage are of an organising pneumonia. The brunt of the disease process of COVID-19 is in the interstitium, thus in the peripheral subpleural and peribronchovascular regions. As the organising pneumonia clears, there are reticular opacities in the subpleural and peribronchial regions. Often there is a subpleural curvilinear line and residual peribronchovascular and subpleural reticular abnormalities which resemble fibrosis seen in ILD. This is the main consideration, are these to be reported as fibrosis? This is important as fibrosis is irreversible. However, with time sometimes even 4-6 months later most of these abnormalities clear up, even the subpleural curvilinear lines. Only very few cases of persistent reticular abnormalities have been seen. Time will tell whether these are also really fibrosis or slow resolving organising pneumonia since these may clear with time.

To call these fibrosis may be a bit premature.

Appendix are a sampling of cases demonstrating progression and regression patterns in COVID-19 pneumonia.